JP2009512673A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009512673A5 JP2009512673A5 JP2008536136A JP2008536136A JP2009512673A5 JP 2009512673 A5 JP2009512673 A5 JP 2009512673A5 JP 2008536136 A JP2008536136 A JP 2008536136A JP 2008536136 A JP2008536136 A JP 2008536136A JP 2009512673 A5 JP2009512673 A5 JP 2009512673A5
- Authority
- JP
- Japan
- Prior art keywords
- sina
- seq
- sirna
- modification
- ribonucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000004048 modification Effects 0.000 claims description 13
- 238000012986 modification Methods 0.000 claims description 13
- 108020004459 Small interfering RNA Proteins 0.000 claims description 12
- 239000005547 deoxyribonucleotide Substances 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 4
- 238000010382 chemical cross-linking Methods 0.000 claims description 3
- 238000007385 chemical modification Methods 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 2
- 102000003566 TRPV1 Human genes 0.000 claims 7
- 101150016206 Trpv1 gene Proteins 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- 239000002773 nucleotide Substances 0.000 claims 7
- 125000003729 nucleotide group Chemical group 0.000 claims 7
- 108091028664 Ribonucleotide Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 239000002336 ribonucleotide Substances 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 229920002477 rna polymer Polymers 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 2
- TWGNOYAGHYUFFR-UHFFFAOYSA-N 5-methylpyrimidine Chemical group CC1=CN=CN=C1 TWGNOYAGHYUFFR-UHFFFAOYSA-N 0.000 claims 2
- LMEHJKJEPRYEEB-UHFFFAOYSA-N 5-prop-1-ynylpyrimidine Chemical compound CC#CC1=CN=CN=C1 LMEHJKJEPRYEEB-UHFFFAOYSA-N 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000002452 interceptive effect Effects 0.000 claims 2
- 150000003212 purines Chemical class 0.000 claims 2
- 150000003230 pyrimidines Chemical class 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0521351.7A GB0521351D0 (en) | 2005-10-20 | 2005-10-20 | Modulation of TRPV expression levels |
| GB0521351.7 | 2005-10-20 | ||
| PCT/GB2006/050342 WO2007045930A2 (en) | 2005-10-20 | 2006-10-20 | Modulation of trpv expression levels |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013007528A Division JP2013074902A (ja) | 2005-10-20 | 2013-01-18 | Ｔｒｐｖ発現レベルの制御 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009512673A JP2009512673A (ja) | 2009-03-26 |
| JP2009512673A5 true JP2009512673A5 (enExample) | 2012-08-09 |
| JP5677721B2 JP5677721B2 (ja) | 2015-02-25 |
Family
ID=35458356
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008536136A Active JP5677721B2 (ja) | 2005-10-20 | 2006-10-20 | Ｔｒｐｖ発現レベルの制御 |
| JP2013007528A Pending JP2013074902A (ja) | 2005-10-20 | 2013-01-18 | Ｔｒｐｖ発現レベルの制御 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013007528A Pending JP2013074902A (ja) | 2005-10-20 | 2013-01-18 | Ｔｒｐｖ発現レベルの制御 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8354385B2 (enExample) |
| EP (1) | EP1937281B1 (enExample) |
| JP (2) | JP5677721B2 (enExample) |
| AT (1) | ATE493994T1 (enExample) |
| AU (1) | AU2006305657B2 (enExample) |
| CA (1) | CA2626181C (enExample) |
| CY (1) | CY1111384T1 (enExample) |
| DE (1) | DE602006019458D1 (enExample) |
| DK (1) | DK1937281T3 (enExample) |
| ES (1) | ES2358538T3 (enExample) |
| GB (1) | GB0521351D0 (enExample) |
| PL (1) | PL1937281T3 (enExample) |
| PT (1) | PT1937281E (enExample) |
| SI (1) | SI1937281T1 (enExample) |
| WO (1) | WO2007045930A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009046059A1 (en) * | 2007-10-01 | 2009-04-09 | Alcon Research, Ltd. | Self complementary aav-mediated delivery of interfering rna molecules to treat or prevent ocular disorders |
| TW200927192A (en) * | 2007-11-19 | 2009-07-01 | Alcon Res Ltd | Use of TRPV1 receptor antagonists for treating dry eye and ocular pain |
| EP2390327A1 (en) * | 2010-05-27 | 2011-11-30 | Sylentis S.A. | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| EP2865759B1 (en) * | 2012-06-20 | 2017-05-17 | NapaJen Pharma, Inc. | Nucleic acid complex and nucleic acid-polysaccharide complex |
| GB201215857D0 (en) | 2012-09-05 | 2012-10-24 | Sylentis Sau | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| KR101681229B1 (ko) | 2013-07-24 | 2016-11-30 | 고려대학교 산학협력단 | TRPV4 활성 억제제로서의 vorinostat의 용도 |
| GB202219829D0 (en) | 2022-12-29 | 2023-02-15 | Ivy Farm Tech Limited | Genetically manipulated cells |
| WO2025215354A1 (en) | 2024-04-08 | 2025-10-16 | Ivy Farm Technologies Limited | Method of culturing an animal cell |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL16768C (enExample) | 1924-10-02 | |||
| US4343794A (en) | 1980-05-06 | 1982-08-10 | Mt. Sinai | Method of reducing intraocular pressure with salts of vanadic acid |
| US4652586A (en) | 1980-11-07 | 1987-03-24 | The General Hospital Corporation | Selective beta-2 adrenergic antagonists for the treatment of glaucoma |
| US4617299A (en) | 1983-12-19 | 1986-10-14 | Knepper Paul A | Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension |
| US5242943A (en) | 1984-03-28 | 1993-09-07 | William J. Louis | 3-aminopropoxyphenyl derivatives, their preparation and pharmaceutical compositions containing them |
| US4812448A (en) | 1984-10-22 | 1989-03-14 | Knepper Paul A | Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension |
| US4757089A (en) | 1985-06-14 | 1988-07-12 | Massachusetts Eye And Ear Infirmary | Increasing aqueous humor outflow |
| US5075323A (en) | 1988-08-24 | 1991-12-24 | Aktiebolaget Hassle | Compounds including omeprazole in the treatment of glaucoma |
| US5260059A (en) | 1989-04-14 | 1993-11-09 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University | Treatment of open-angle glaucoma by modulation matrix metalloproteinases and their inhibitor |
| US6372249B1 (en) | 1991-12-16 | 2002-04-16 | Baylor College Of Medicine | Senscent cell-derived inhibitors of DNA synthesis |
| US5464866A (en) | 1992-08-17 | 1995-11-07 | Alcon Laboratories, Inc. | Substituted hydrindanes for the treatment of angiogenesis-dependent diseases |
| US5545626A (en) | 1994-01-19 | 1996-08-13 | The Trustees Of Columbia University In The City Of New York | Method of treating glaucoma with oligonucleotides |
| US5585401A (en) | 1994-12-09 | 1996-12-17 | The Reents Of The University Of California | Method for enhancing outflow of aqueous humor in treatment of glaucoma |
| US20020055536A1 (en) | 1996-09-26 | 2002-05-09 | Dewitte Robert S. | System and method for structure-based drug design that includes accurate prediction of binding free energy |
| US6489307B1 (en) | 1998-09-14 | 2002-12-03 | University Of Florida | Antisense compositions targeted to β1-adrenoceptor-specific mRNA and methods of use |
| WO2000044914A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| US6365576B1 (en) | 1999-06-24 | 2002-04-02 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Method for inhibiting herpes infection |
| RU2322500C2 (ru) | 2000-12-01 | 2008-04-20 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. | Малые молекулы рнк, опосредующие интерференцию рнк |
| US20020165158A1 (en) | 2001-03-27 | 2002-11-07 | King George L. | Methods of modulating angiogenesis |
| US20040209832A1 (en) | 2001-11-30 | 2004-10-21 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US20070049543A1 (en) | 2001-05-18 | 2007-03-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA |
| AU2002361861A1 (en) | 2001-12-21 | 2003-07-30 | Rhode Island Hospital | SELECTIVE 11Beta-HSD INHIBITORS AND METHODS FOR USE THEREOF |
| US7294504B1 (en) | 2001-12-27 | 2007-11-13 | Allele Biotechnology & Pharmaceuticals, Inc. | Methods and compositions for DNA mediated gene silencing |
| GB2406568B (en) | 2002-02-20 | 2005-09-28 | Sirna Therapeutics Inc | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| CA2482904A1 (en) | 2002-04-18 | 2003-10-23 | Lynkeus Biotech Gmbh | Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification |
| US20040115641A1 (en) | 2002-12-11 | 2004-06-17 | Isis Pharmaceuticals Inc. | Modulation of ROCK 1 expression |
| WO2004009794A2 (en) | 2002-07-24 | 2004-01-29 | Immusol, Inc. | NOVEL siRNA LIBRARIES AND THEIR PRODUCTION AND USE |
| US20040115815A1 (en) | 2002-07-24 | 2004-06-17 | Immusol, Inc. | Single promoter system for making siRNA expression cassettes and expression libraries using a polymerase primer hairpin linker |
| ES2280826T5 (es) | 2002-08-05 | 2017-08-03 | Silence Therapeutics Gmbh | Nuevas formas adicionales de moléculas de ARN de interferencia |
| US20040029275A1 (en) * | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
| ATE513843T1 (de) | 2002-09-25 | 2011-07-15 | Univ Massachusetts | Abstellen von genen in vivo durch chemischmodifizierte und stabile sirna |
| KR20120038546A (ko) | 2002-11-01 | 2012-04-23 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | ＨＩＦ-1 알파의 ｓｉＲＮＡ 억제를 위한 조성물 및 방법 |
| DE10322662A1 (de) * | 2002-11-06 | 2004-10-07 | Grünenthal GmbH | Wirksame und stabile DNA-Enzyme |
| DK2284266T3 (da) | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| US20060257851A1 (en) | 2002-11-26 | 2006-11-16 | Itzhak Bentwich | Bioinformatically detectable group of novel viral regulatory genes and uses thereof |
| US20040167090A1 (en) | 2003-02-21 | 2004-08-26 | Monahan Sean D. | Covalent modification of RNA for in vitro and in vivo delivery |
| GB0307206D0 (en) | 2003-03-28 | 2003-04-30 | Axordia Ltd | Hyperproliferation |
| US20040198640A1 (en) | 2003-04-02 | 2004-10-07 | Dharmacon, Inc. | Stabilized polynucleotides for use in RNA interference |
| WO2004099372A2 (en) | 2003-05-01 | 2004-11-18 | University Of Florida | Anti-scarring ribozymes and methods |
| US20040224405A1 (en) | 2003-05-06 | 2004-11-11 | Dharmacon Inc. | siRNA induced systemic gene silencing in mammalian systems |
| WO2005044976A2 (en) | 2003-06-20 | 2005-05-19 | Isis Pharmaceuticals, Inc. | Oligomeric compounds for use in gene modulation |
| US7338950B2 (en) * | 2003-10-07 | 2008-03-04 | Renovis, Inc. | Amide compounds as ion channel ligands and uses thereof |
| WO2005045037A2 (en) | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| KR20050039573A (ko) * | 2003-10-23 | 2005-04-29 | 주식회사 태평양 | 티오우레아계 유도체의 용해성과 생체이용률이 개선된약제학적 조성물 |
| US20050208658A1 (en) | 2003-11-21 | 2005-09-22 | The University Of Maryland | RNA interference mediated inhibition of 11beta hydroxysteriod dehydrogenase-1 (11beta HSD-1) gene expression |
| US7544803B2 (en) * | 2004-01-23 | 2009-06-09 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| US20090247604A1 (en) | 2004-02-05 | 2009-10-01 | Intradigm Corporation | RNAi Therapeutics for Treatment of Eye Neovascularization Diseases |
| GB0403600D0 (en) | 2004-02-18 | 2004-03-24 | Trinity College Dublin | Methods and reagents for treating disease |
| AU2005222902B2 (en) | 2004-03-12 | 2010-06-10 | Alnylam Pharmaceuticals, Inc. | iRNA agents targeting VEGF |
| KR101147147B1 (ko) | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
| WO2005117938A2 (en) | 2004-04-13 | 2005-12-15 | Regents Of The University Of Minnesota | Methods of treating ocular conditions |
| EP1768954A4 (en) | 2004-06-24 | 2008-05-28 | Incyte Corp | 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS |
| EP2990410A1 (en) | 2004-08-10 | 2016-03-02 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
| WO2006021817A2 (en) | 2004-08-23 | 2006-03-02 | Sylentis S.A.U. | Treatment of eye disorders characterized by an elevated introacular pressure by sirnas |
| TW200639253A (en) | 2005-02-01 | 2006-11-16 | Alcon Inc | RNAi-mediated inhibition of ocular targets |
| BRPI0609206A2 (pt) | 2005-03-11 | 2010-03-02 | Alcon Inc | inibiÇço mediada por rnai de proteÍna relacionada frizzled-1 para tratamento de glaucoma |
-
2005
- 2005-10-20 GB GBGB0521351.7A patent/GB0521351D0/en not_active Ceased
-
2006
- 2006-10-20 AT AT06794999T patent/ATE493994T1/de active
- 2006-10-20 US US12/090,426 patent/US8354385B2/en active Active
- 2006-10-20 PL PL06794999T patent/PL1937281T3/pl unknown
- 2006-10-20 ES ES06794999T patent/ES2358538T3/es active Active
- 2006-10-20 AU AU2006305657A patent/AU2006305657B2/en active Active
- 2006-10-20 JP JP2008536136A patent/JP5677721B2/ja active Active
- 2006-10-20 CA CA2626181A patent/CA2626181C/en active Active
- 2006-10-20 DE DE602006019458T patent/DE602006019458D1/de active Active
- 2006-10-20 SI SI200630965T patent/SI1937281T1/sl unknown
- 2006-10-20 DK DK06794999.0T patent/DK1937281T3/da active
- 2006-10-20 EP EP06794999A patent/EP1937281B1/en active Active
- 2006-10-20 PT PT06794999T patent/PT1937281E/pt unknown
- 2006-10-20 WO PCT/GB2006/050342 patent/WO2007045930A2/en not_active Ceased
-
2011
- 2011-04-05 CY CY20111100350T patent/CY1111384T1/el unknown
-
2013
- 2013-01-18 JP JP2013007528A patent/JP2013074902A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6453275B2 (ja) | 非対称性干渉ｒｎａの組成物およびその使用 | |
| DK3222724T3 (en) | ADDITIONALLY UNKNOWN FORMS OF INTERFERRING RNA MOLECULES | |
| US10590423B2 (en) | Treatment of age-related macular degeneration using RNA complexes that target MyD88 or TLR3 | |
| JP2020039361A (ja) | 筋強直性ジストロフィープロテインキナーゼ（ｄｍｐｋ）の発現を調節するための化合物及び方法 | |
| TW201920227A (zh) | 用於抑制脂蛋白元C-III (APOC3)表現之RNAi試劑及組合物 | |
| CA3064590A1 (en) | Two-tailed self-delivering sirna and related methods | |
| US20200109405A1 (en) | TREATMENT OF ATOPIC DERMATITIS AND ASTHMA USING RNA COMPLEXES THAT TARGET IL4Ra, TRPA1, OR F2RL1 | |
| JP2014097072A5 (enExample) | ||
| CN104379152B (zh) | 寡核苷酸螯合物方法 | |
| JP2023539341A (ja) | Ｄｕｘ４阻害剤およびその使用方法 | |
| TW201336514A (zh) | ＲＮＡ干擾（ＲＮＡｉ）所媒介之與脾酪胺酸激酶相關之發炎症狀的抑制作用（二） | |
| JP2009512673A5 (enExample) | ||
| CA3017326A1 (en) | Allele-specific gene suppression | |
| RU2008121265A (ru) | Малые интерферирующие олигонуклеотиды, содержащие арабинозо-модифицированные нуклеотиды | |
| WO2025002247A1 (zh) | 靶向人血管生成素样蛋白3的核酸及其用途 | |
| JP6830441B2 (ja) | 治療上のｕｎａオリゴマーおよびその使用 | |
| WO2007084359A2 (en) | Compositions and methods for the treatment of influenza infection | |
| WO2014009609A1 (en) | Combination therapy iii | |
| JP2023123463A (ja) | 疼痛障害の治療のための組成物および方法 | |
| RU2788030C2 (ru) | Структуры мирнк с высокой активностью и сниженным воздействием вне мишени | |
| CN115605592A (zh) | 用于治疗神经系统疾病的补体组分c1r抑制剂以及相关的组合物、系统和使用它们的方法 | |
| AU2018200311A1 (en) | Further novel forms of interfering rna molecules | |
| HK1194764A (en) | Biologically active nucleotide molecules for selectively killing off cells, use thereof, and application kit |